Mechanism of action<unk>  binds to interleukin 17 (IL-17A), a pro-inflammatory cytokine, and blocks its action. Among other things, IL-17A stimulates proliferation and activation of keratinocytes in the skin. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which binds to the interleukin-17 receptor. The antibody has affinity to the homodimer IL-17A and the heterodimer IL-17A/F, but not to other members of the interleukin 17 family. Pharmacokinetics After subcutaneous injection,<unk>  has a bioavailability of 54–90%. Highest blood plasma concentrations are reached after four to seven days after a single dose. With the usual dosing scheme (loading plus a dose every two weeks), steady state concentrations are reached in the eighth week on average. Like other antibodies,<unk>  is probably degraded by proteolysis. Its elimination half-life is 13 days.
Ixekizumab
Caplacizumab
Satralizumab
Risankizumab
Brolucizumab
Bimekizumab
Tocilizumab
Etaracizumab